Rebekka Wegmann

Oct 29, 2024 | nature.com | Rebekka Wegmann |Ximena Bonilla |Ricardo Coelho |Sandra Goetze |Francis Jacob |Jack Kuipers | +17 more

AbstractDeep single-cell multi-omic profiling offers a promising approach to understand and overcome drug resistance in relapsed or refractory (rr) acute myeloid leukemia (AML). Here, we combine single-cell ex vivo drug profiling (pharmacoscopy) with single-cell and bulk DNA, RNA, and protein analyses, alongside clinical data from 21 rrAML patients.